Skip to main content

Cold Agglutinin Disease (CAD)

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Recordati
RecordatiFrance - Saint-Victor
1 program
SutimlimabN/AMonoclonal Antibody1 trial
Active Trials
NCT05791708Active Not Recruiting429Est. Nov 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
RecordatiSutimlimab

Clinical Trials (1)

Total enrollment: 429 patients across 1 trials

Cold Agglutinin Disease Real World Evidence Registry

Start: Dec 2019Est. completion: Nov 2028429 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.